A multicenter, international, randomized, placebo controlled, double-blind, parallel group and

event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the

prevention of ischemic stroke in male and female participants aged 18 years and older after an

acute non-cardioembolic ischemic stroke or high-risk TIA

National Leader: Professor Bruce Campbell

Lead HREC: Professor Bruce Campbell

Status: ASTN Endorsed, Site Initiation Visits starting Feb2023

No. of Patients Currently Recruited:       0                         No. of Patients Required:  308

Participating Australian Sites:

  1. Bruce Campbell, Royal Melbourne Hospital, VIC
  2. Tim Kleinig, Royal Adelaide Hospital, SA
  3. Dennis Cordato, Liverpool Hospital, NSW
  4. Carlos Garcia Esperon, John Hunter Hospital, NSW
  5. Peter Bailey, Gold Coast University Hospital, QLD
  6. Miriam Priglinger, Royal Nortshore Hospital, NSW
  7. Ken Butcher, Prince of Wales Hospital, NSW
  8. Philip Choi, Box Hill Hospital, VIC
  9. Andrew Moey, Lyell McEwin Hospital, SA
  10. Michael Devlin, Princess Alexandra Hospital, QLD
  11. Rohan Grimley, Sunshine Coast University Hospital, QLD
  12. Ramesh Sahathevan, Grampians Health, Ballarat, VIC
  13. Andrew Wong, Royal Brisbane & Women’s Hospital, QLD
  14. Craig Anderson, Royal Prince Alfred Hospital, NSW
  15. Darshan Ghia, Fiona Stanley Hospital, WA
  16. Geoff Cloud, The Alfred Hospital, VIC
  17. Robert Boland-Freitas, Blacktown Hospital, NSW
  18. Tissa Wijeratne, Western Health, VIC
  19. Shaloo Singhal, Monash Health, VIC
  20. Thomas Chemmanam, Sir Charles Gairdner Hospital, WA
  21. Chong Wong, Westmead Hospital, NSW
  22. Sameen Haque, Nepean Hospital, NSW
30 December 2022

Related Posts